Sanofi Stock News

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant women and Dupixent as a treatment option for skin rash had to be halted. Here are the key catalysts for the unfolding week: Conferences 49th Annual Scientific and Technology Meeting of the American Auditory Society, AAS (hybrid event) Feb. 24-27, in Scottsdale, Arizona & online Multidisciplinary Head and Neck Cancers Symposium (virtual event): Feb. 24-27, in Phoenix, Arizona & online International Society of Nephrology''s World Congress of Nephrology, or WCN, 2022 (hybrid event): Feb. 24-27, in Kuala Lumpur & online PDUFA Dates The FDA has set a PDUFA date of Friday, Feb. 25, for its new drug application for Reata Pharmaceuticals, Inc.''s (NASDAQ: RETA ) Bardoxolone.

GlaxoSmithKline is pausing trials of an respiratory syncytial virus vaccine in pregnant women. Sanofi is halting a trial of its drug Dupixent as a treatment…

Dublin, Feb. 18, 2022 (GLOBE NEWSWIRE) -- The "Global Organ Transplantation Market (2021-2026) by Treatment, Organ, Product, Transplant, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Organ Transplantation Market is estimated to be USD 12.95 Bn in 2021 and is expected to reach USD 22.1 Bn by 2026, growing at a CAGR of 11.28%. Market Dynamics Factors for Driving the market are demand for tissue and organ plantation is high for organ failure treatment. Organ failure occurs due to various factors such as frivolous trauma, loss of blood, poisoning, drug abuse, etc. The increasing prevalence of renal disease, overconsumption of alcohol, and unhealthy diet have provided a push for the growth of the Organ Transplantation market. Huge population suffering from chronic illness and organ failure. Treatment of failure contributing to the development and Technological advancement and increasing issue banks are also boosting the market.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios''s Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO ) said the U.S. Food and Drug Administration has approved its Pyrukynd (mitapivat) in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare, debilitating, lifelong hemolytic anemia, or an accelerated destruction of red blood cells. The company said it expects the treatment to be made available in the U.S. two weeks after the approval. The stock was up 2.95% to $30.33 in premarket trading. Click here to access Benzinga''s FDA Calendar Regeneron, Sanofi Halt Late-Stage Study Of Dupixent In Treating Skin Rash Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi (NASDAQ: SNY ) announced a Phase 3 trial evaluating their co-developed Dupixent in patients with chronic spontaneous urticaria will stop due to futility, based on a pre-specified interim analysis. The trial, which assessed Dupixent added to antihistamines in patients refractory to omalizumab at 24 weeks, showed positive numerical trends in reducing itch and hives but didn''t meet statistical …

Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab) in chronic spontaneous urticaria (CSU). The trial included CSU patients who don''t respond to biologic treatment, Novartis AG (NYSE: NVS ) / Roche Holdings AG''s (OTC: RHHBY ) Xolair (omalizumab). CSU is a severe form of … Full story available on Benzinga.com

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) are stopping a phase 3 trial (CUPID STUDY B) of Dupixent (dupilumab) in patients with chronic spontaneous urticaria ((CSU)) due…

Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab) in chronic spontaneous urticaria (CSU).

If history is any guide, there may be good fortune ahead for shares of Sanofi (NASDAQ: SNY ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses … Full story available on Benzinga.com

New York, USA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Orthobiologics Market is Anticipated to Grow at a CAGR of 4.44% During the Forecast Period (2021-26) | DelveInsight As per DelveInsight analysis, a growing geriatric population at risk of developing various bone degenerative disorders, an increase in traumatic injuries such as car accidents, sports injuries, and others are expected to boost the Orthobiologics market growth. Furthermore rising investments in R&D and collaborations by key manufacturers, as well as an increase in various orthobiologic product approvals will also drive the market. DelveInsight''s Orthobiologics Market Insights and Forecast report provides the current and forecast Orthobiologics market, upcoming developments in the medical devices, individual market shares, challenges, drivers, barriers, market growth trends, and key players in the Orthobiologics market. Some of the Key Highlights from the Orthobiologics Market Report According to DelveInsight analysis, North America is expected to dominate the overall Orthobiologics Market during the forecasted period.

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

The FDA has accepted for Priority Review the supplemental marketing application for Dupixent (dupilumab) for children aged six months to 5 years with moderate-to-severe atopic dermatitis. Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceutical Inc (NASDAQ: REGN ) are developing Dupilumab. The application covers Dupixent as an add-on maintenance treatment for atopic dermatitis patients whose disease is not adequately controlled with topical prescription therapies or when those … Full story available on Benzinga.com

Regeneron (REGN) and Sanofi get Priority Review for their sBLA in the United States seeking label expansion of Dupixent.

The U.S. Food and Drug Administration granted priority review to Regeneron Pharmaceutical (REGN) and Sanofi (SNY)''s application seeking approval of Dupixent (dupilumab) as an